Artivion (AORT) to Release Earnings on Thursday

Artivion (NYSE:AORT) is scheduled to release its earnings data after the market closes on Thursday, August 8th. Analysts expect Artivion to post earnings of $0.03 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. Artivion had a negative net margin of 2.61% and a positive return on equity of 3.64%. The firm had revenue of $97.43 million for the quarter, compared to analysts’ expectations of $92.30 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Artivion Price Performance

Artivion stock opened at $25.40 on Wednesday. The company’s fifty day moving average price is $25.28 and its 200 day moving average price is $21.99. Artivion has a 1 year low of $12.16 and a 1 year high of $29.24. The stock has a market capitalization of $1.06 billion, a P/E ratio of -105.83 and a beta of 1.75. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.26 and a current ratio of 6.04.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Lake Street Capital lifted their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Stifel Nicolaus lifted their price target on shares of Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, Needham & Company LLC lifted their price target on shares of Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.